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2. Summary 
 
Epithelial ovarian cancer is one of the most lethal gynaecological malignancies, 
which is due to the diagnosis in an advanced stage and the resistance to 
conventional chemotherapies. Therefore, it is an urgent need to identify new 
diagnostic, prognostic and therapeutic molecules. In the setting of translational 
research, such molecular markers can be determined in tumor tissue and can be 
used for estimation of patient prognosis, planning of treatment strategies, and for 
prediction of therapy response. In this thesis, we investigated the expression of 
molecular markers in primary human ovarian carcinomas and compared expression 
data with clinical and pathological characteristics as well as patient survival. The 
molecules were further characterized by functional analyses in cell culture studies.  
Seven original publications are presented: 
 1.) We investigated the expression of the actin-binding protein Gelsolin in 
ovarian carcinomas and found a loss at protein and RNA levels. In cell culture, we 
demonstrated tumor growth suppressive activity of Gelsolin and that epigenetic 
modification might be responsible for its down-regulation in ovarian cancer [1].   
 2.) We analyzed the expression of the nuclear export protein CRM1. We 
observed a protein expression in a subset of ovarian carcinomas related to an 
aggressive biological behaviour. Inhibition of CRM1 with Leptomycin B resulted in 
suppression of cyclooxygenase-2 expression, reduction in cell proliferation, and 
induction of apoptosis in ovarian cancer cells [2]. 
 3.) We investigated the expression of AKT and members of the mTOR 
pathway. We observed an increased AKT protein expression in ovarian carcinomas 
that was associated with advanced disease stage. We found AKT1 and AKT2 mRNA 
expression in cancer cell lines but no relevant AKT3 mRNA levels using RT-PCR. 
Treatment of cancer cells with the unselective PI3K inhibitor LY294002 and RNA 
interference to selectively inhibit the AKT isoforms resulted in reduction of cell 
proliferation. Our findings show that AKT, especially the AKT2 isoform might be 
responsible for ovarian cancer progression [3]. Since the PI3K/AKT pathway plays an 
important role in ovarian cancer, we consecutively analyzed downstream molecules 
like mTOR, 4E-BP1, and eIF4E. It has been shown that mTOR is an attractive target 
in anticancer therapy and as a basis for clinical trials, it is necessary to identify 
patients who will profit of this therapy and to determine the status of these molecular 
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targets in tumor tissues. Protein expression of p-mTOR was significantly associated 
with p-eIF-4E expression and serous subtype. For p-4E-BP1, a significant relation to 
poorly differentiated carcinomas was observed. In Kaplan-Meier analysis, increased 
expression of p-mTOR and p-eIF-4E was related to better overall survival in ovarian 
cancer patients. Following, we connected the in vivo data with cell culture studies and 
found a different protein expression pattern of p-AKT, p-mTOR, and p-4E-BP1 in ten 
ovarian cancer cell lines. We treated cancer cells with the mTOR inhibitor Rapamycin 
and observed an inhibition of cell proliferation and a suppression of p-mTOR and p-
4E-BP1 as well as an up-regulation of p-AKT in cancer cell lines. These data support 
that this pathway is important in ovarian cancer progression and may serve as a 
therapeutic target [4].  
4.) We observed an expression of HMGA2 in serous ovarian carcinomas using 
in situ RNA hybridization as well as at mRNA and protein levels in cancer cells using 
RT-PCR and western blot. Transient silencing of HMGA2 gene by siRNA inhibited 
proliferation of those cancer cells which over-express this gene initially. Stable 
silencing of highly expressed HMGA2 gene by shRNAi in cancer cells resulted in 
growth inhibition. The anti-tumoral effect of HMGA2 knockdown was confirmed in 
vivo, administration of a HMGA2-targeting construct resulted in suppression of 
subcutaneous tumor xenografts in athymic nude mice. These findings suggest that 
the HMGA2 gene represents a promising target for gene silencing therapy in ovarian 
cancer [5].  
5.) We investigated the hypothesis that gene expression analysis of ovarian 
carcinomas may be used to identify patients with different outcomes independently of 
classical clinical predictors. We used a semi-supervised method for prediction of 
overall survival. Affymetrix gene expression analysis from 80 ovarian carcinomas 
(TOC cohort) was used for the development of a predictive model. A 300-gene 
ovarian prognostic index was generated and validated in a leave-one-out approach. 
The prognostic power of this index was confirmed in an independent data set of 118 
ovarian carcinomas (Dukes cohort). In multivariate analysis, the ovarian prognostic 
index was independent of the post-operative residual tumor. We then constructed a 
combined score of the molecular data and residual tumor status, which was able to 
define patient groups with highly significant differences in survival. Our findings 
suggest that gene expression analysis can be used to generate prognostic 
signatures in ovarian cancer that can be validated in independent data sets [6]. 
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6.)  We analyzed the expression of the IGF-II mRNA-binding protein IMP3 in 
ovarian carcinomas. Increased IMP3 protein and mRNA expression was associated 
with better overall survival indicating that IMP3 might be involved in progression of 
ovarian cancer [7].  
These findings provide insights in molecular mechanisms of ovarian cancer 
progression. Some of these molecules show potential prognostic impact or may 
function as therapeutic targets in this disease. The design of future clinical trials 
should incorporate biomarker testing to determine predictive markers for response to 
specific inhibitors. 
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3. Introduction 
 
3.1. Epidemiology and conventional prognostic factors 
 
Epithelial ovarian cancer is the fifth most common cause of cancer death and has the 
highest mortality rate among gynaecological malignancies in the Western world with 
estimated 14,600 deaths (5% of all cancer caused deaths in women) in the United 
States in 2009 [8]. It accounts for approximately 85% of all ovarian malignancies [9] 
and has an estimated incidence of 21,550 cases (3% of all cancer diseases in 
women) in the USA in 2009 [8]. Due to the lack of early clinical symptoms, the 
majority of the patients presents with an advanced disease stage. So far, there is no 
screening-method for early detection. 
Traditional prognostic clinical and pathological factors in ovarian cancer are patient 
age, tumor stage (according to the FIGO classification), lymph node status, tumor 
grade, and histological subtype [10,11]. However, the most important prognostic 
factor in these patients is residual tumor after primary surgery [12,13]. 
In FIGO stage I, the disease is confined to the ovary and the 5-year survival rate is 
90% but only 25% of all cases are detected at this early stage. FIGO stage II is 
characterized by pelvic extension of the carcinoma and a 5-year survival rate 
between 40-70%. FIGO III is the most common stage at time of diagnosis and 
classified when carcinoma disseminates in the upper abdomen or lymph node 
metastases occur (5-year survival less than 40%). In FIGO stage IV, the carcinoma is 
metastasized to distant sites and the 5-year survival rate is less than 20% [14].  
Epithelial ovarian carcinomas show a heterogeneous morphology and can be 
subdivided in the main histological subtypes: serous, mucinous, endometrioid, and 
clear cell carcinomas [15].  Molecular studies have supported that these histological 
types are associated with different biological behaviour and response to 
chemotherapy [16]. 
 
3.2. Genetic alterations in ovarian cancer 
 
The histological subtypes reflect different genetic alterations. For the most common 
serous subtype, two pathogenetic pathways were recently proposed [17]: The type I 
pathway is characterized by a step-wise process of frequent mutations in KRAS, 
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BRAF, ERBB2 and results in a low-grade serous carcinoma. Morphologic and 
molecular observations indicate a development from a benign serous tumor which 
progresses to a borderline tumor, and than to an invasive carcinoma. In contrast, the 
type II pathway contributes to high-grade serous carcinomas and is characterized by 
mutations in TP53 in 80%, high level of chromosomal instability, and absence of 
mutations in KRAS, BRAF, and ERBB2. Precursor lesions are very rarely detected. 
Ovarian surface epithelium or inclusion cysts are proposed as the origin site for some 
tumors [18]. Due to the rapid development of this tumor type it has been also 
suggested that they arise de novo [19]. Recently, a tubal origin was suggested [20] 
because approximately half of the high-grade serous carcinomas are associated with 
tubal intraepithelial carcinoma both showing identical TP53 mutations. Less is known 
about the genesis of the other histological types. It is assumed that mucinous, 
endometrioid, and clear cell carcinomas also evolve in the same manner as type I 
serous cancer [17]. Endometrioid and clear cell tumors have been associated with 
endometriosis that is regarded as the precursor of these tumors [21]. Hereditary 
ovarian cancer occurs in 10% and is related to germline mutations in BRCA1/BRCA2 
and Mismatch-Repair-Genes. Most of the BRCA-associated carcinomas are of the 
high-grade serous subtype [22]. 
 
3.3. Molecular prognostic and predictive factors  
 
Conventional clinico-pathological factors do not accurately classify ovarian cancer 
patients in relation to clinical outcome and benefit of adjuvant systemic treatment. 
Due to the rapid and unfavourable clinical course, it is an urgent need to identify 
molecular parameters which are useful in estimation of patient prognosis, planning of 
treatments, and selection of patients who will have a benefit of standard 
chemotherapies or may profit from novel molecular therapeutic strategies.  
Despite many efforts in ovarian cancer research, reliable prognostic and predictive 
biomarkers are still lacking. Several gene expression profiling studies were 
performed but these gene expression signatures have not been adequately validated 
in other data sets so far and show very little overlap [23,24].  
 
3.4. Current treatment concepts 
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The current standard therapy is surgical treatment followed by systemic 
chemotherapy. Since residual tumor after surgery is the main prognostic factor for 
overall survival in ovarian cancer, optimal surgical debulking remains key treatment. 
Adjuvant systemic therapy is based on carboplatin in combination with a taxane [25]. 
Only 15-20% of the patients will experience a long time remission after chemotherapy 
[26]. The majority of the patients show a good response on primary systemic therapy 
but most of them evolve resistance and will relapse from this disease. New cytotoxic 
drugs have entered clinical trials which are promising to overcome drug-resistance. 
Further, small-molecule inhibitors and monoclonal antibodies that target molecules 
(“targeted therapies”) of angiogenesis, cell survival and cell growth are now entering 
clinical trials [27].  
 
3.5. Aim of this thesis 
 
In this study we aimed to identify molecular markers which may be helpful in the 
assessment of patient prognosis as well as may serve as novel therapeutic targets. 
Therefore, we investigated the expression of several molecules in ovarian cancer 
tissue and combined in vivo findings with additional cell culture studies.  
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4. Studies of the thesis 
 
4. 1. Loss of Gelsolin expression in human ovarian carcinomas 
Noske A, Denkert C, Schober H, Sers C, Zhumabayeva B, Weichert W, Dietel M, 
Wiechen K. Eur J Cancer 2005; 41: 461-469  
 
In the first study, we investigated the expression of Gelsolin, an actin-binding protein, 
which is involved in the modulation of the actin cytoskeleton and regulation of cell 
growth and cell motility. First, we identified a differential gene expression of Gelsolin 
in ovarian carcinomas and normal ovarian tissues using a Cancer Profiling Array. In 
this cDNA array, we found decreased Gelsolin expression levels as compared to 
normal tissue. We further evaluated the Gelsolin expression at protein levels in 110 
ovarian tissue samples and in six ovarian cancer cell lines. We observed a reduced 
expression of Gelsolin in borderline tumors and primary ovarian carcinomas 
compared with the epithelium of normal ovaries and benign tumors by 
immunohistochemistry. Decreased expression was associated with poorly 
differentiated (high-grade) carcinomas. No association with other clinico-pathological 
factors or patient survival was found. Low protein levels of Gelsolin were observed in 
four of six ovarian cancer cell lines. In addition, we investigated the growth regulatory 
function of Gelsolin in ovarian cancer cell lines using cDNA transfections. Re-
expression of Gelsolin in OAW42 and ES-2 cells resulted in a suppression of tumor 
cell survival in vitro. To evaluate whether epigenetic modification is responsible for 
the decreased Gelsolin expression in ovarian cancer cells, we treated cells with 
inhibitors of DNA methylation (5-aza-2’deoxycytidine) and histone deacetylation 
(Trichostatin A). We observed a strong up-regulation of Gelsolin in OAW42 and 
OVCAR3 cells. 
In summary, these findings demonstrate a role of Gelsolin in progression of ovarian 
cancer. The protein revealed growth suppressive activity in ovarian cancer cells. 
Down-regulation of Gelsolin might be mediated by epigenetic modification. It is 
known that genes affected by epigenetic events may serve as new targets in anti-
cancer therapy. Thus, reconstitution of Gelsolin by inhibitors of histone deacetylase 
could be a promising therapeutic intervention in ovarian cancer.   
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Figure 1 Immunhistochemical expression of Gelsolin in normal (A) and benign 
ovarian tissue (B) but loss of Gelsolin expression in a high-grade ovarian carcinoma 
(C). Western Blot analysis demonstrates decreased Gelsolin expression in four 
ovarian cancer cell lines (D). Gelsolin expression can be reconstituted in OVCAR-3 
cells after treatment with inhibitors of DNA methylation and histone deacetylase (E).  
Colony formation assay indicates growth suppression of OAW-42 and ES-2 cells 
following transfection with a gelsolin expression vector (LKCG). 
 
 
4. 2. Expression of the nuclear export protein chromosomal region 
maintenance/exportin 1/Xpo1 is a prognostic factor in human ovarian cancer 
Noske A, Weichert W, Niesporek S, Röske  A, Buckendahl AC, Koch I, Sehouli J, 
Dietel M, Denkert C. Cancer 2008; 112: 1733-1743 
 
In this study, we investigated the expression of CRM1 (chromosomal region 
maintenance/ exportin 1/ Xpo1) in primary ovarian carcinomas (n=74) and ovarian 
cancer cell lines (n=11). CRM1 is important in at least two areas of cellular function. 
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On the one hand, it serves as a nuclear-cytoplasmic transport protein and mediates 
an increasing number of molecules, like i. a. p53, AKT1, EGFR, and others. On the 
other hand, CRM1 is involved in control of chromosome structure during mitosis. It 
controls chromosome segregation and prevents chromosome reduplication. We 
observed a nuclear and cytoplasmic expression of CRM1 in 52.7% and 56.8% of the 
primary invasive ovarian carcinomas by immunohistochemistry but only low 
expression in borderline tumors (7.1%), and no expression in normal or benign 
ovarian tissue samples. Nuclear CRM1 expression was significantly associated with 
increased cyclooxygenase-2 expression. While, cytoplasmic CRM1 expression was 
significantly related to poorly-differentiated (high-grade) carcinomas, higher mitotic 
rate as well as advanced tumor stage. In univariate Kaplan-Meier analysis, nuclear 
CRM1 expression was significantly associated with poor overall survival for ovarian 
cancer patients but reached no independent prognostic significance. In western blot, 
we found a protein expression of CRM1 in various cancer cell lines, but reduced 
levels in immortalized human ovarian surface epithelial (HOSE) cells. Since COX-2 is 
an independent prognostic factor for overall survival in ovarian cancer patients 
(Denkert et al. 2002), we were interested to investigate a potential interaction 
between COX-2 and CRM1. We further aimed to evaluate the function of CRM1 in a 
cell culture model. We observed a suppression of COX-2 protein levels after 
incubation of OVCAR-3 cells with Leptomycin B (LMB), a specific inhibitor of CRM1. 
Further, CRM1 inhibition by LMB results in a significant reduction in cell proliferation 
using a XTT assay, decreased the percentage of cells in G1 phase, and induced 
apoptosis measured by using of different assays (FACS, caspase-3 activity, FITC-
deoxyuridine triphosphate Apo Direct).  
Our findings demonstrate that CRM1 is an interesting molecular marker for advanced 
and aggressive ovarian cancer. The combination of functional and in vivo data 
suggests that CRM1 may play a role in the regulation of COX-2 in ovarian cancer. 
Inhibition of the nuclear export of tumor relevant signalling molecules like COX-2, 
EGFR, p53, and others may play an important role in anticancer treatment. Novel 
CRM1 antagonists such as PKF050-638 or 5219668 have been recently identified 
and may be potential agents in targeted therapies. 
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Figure 2 Immunohistochemical expression of CRM1: No immunoreaction in normal 
tissue (A) but intense expression in a borderline tumor (B), and invasive ovarian 
cancer (C, D). Kaplan-Meier analysis shows a significantly reduced overall survival in 
patients with CRM1 positive ovarian cancer (E). Western blot demonstrates a protein 
expression of CRM1 in ovarian cancer cell lines (F). COX-2 is highly inducible after 
treatment with IL-1β in OVCAR-3 cells (G). Incubation with Leptomycin B (LMB) 
results in COX-2 suppression at protein level (G). LMB-treated cells OVCAR-3 show 
an increased sub-G0/G1-peak and a decreased G1-phase compared with untreated 
cells (H). Flow cytometry indicates an increased apoptotic cell population in LMB-
treated cells, represented by active caspase-3 in the M2 gate (I). 
 
 
4. 3. Specific inhibition of AKT2 by RNA interference results in reduction of 
ovarian cancer cell proliferation: increased expression of AKT in advanced 
ovarian cancer  
Noske A, Kaszubiak A, Weichert W, Sers C, Niesporek S, Koch I, Schaefer B, 
Sehouli J, Dietel M, Lage H, Denkert C. Cancer Lett 2007; 246: 190-200 
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In this study, we investigated the AKT expression in ovarian carcinomas and the role 
of AKT isoforms to ovarian cancer cell proliferation. The protein kinase AKT/PKB 
family has three members (AKT1, 2, and 3) but their cellular functions are not 
completely elucidated. AKT is known as a central signalling molecule in tumor 
relevant pathways and mediates cell survival. In an immunohistochemical analysis, 
we observed an increased AKT expression in 58% of the primary ovarian carcinomas 
as compared to normal ovaries. AKT expression was significantly associated with 
positive lymph node stage and advanced FIGO stage. In western blot analysis, total 
AKT expression was found in all (four) ovarian cancer cell lines, whereas the 
phosphorylated form was only present in OVCAR-3 and SKOV-3 cells. To evaluate 
the expression of the AKT isoforms, we used conventional and quantitative RT-PCR. 
We observed an AKT1 and AKT2 expression at the mRNA level in all cell lines, while 
no relevant AKT3 mRNA levels were detected. To determine the effects on cell 
proliferation, we used the unselective PI3K inhibitor LY294002 and RNA interference 
to selectively inhibit the AKT isoforms. Treatment with LY294002 and AKT2 siRNA 
reduced proliferation of OVCAR-3 cells. These findings show a role for AKT in 
ovarian cancer progression. Especially the AKT2 isoform might be responsible for 
ovarian cancer cell proliferation. Accordingly, AKT is an interesting target for 
therapeutic intervention. Meanwhile, inhibitors of AKT and PI3K (upstream of AKT) 
have entered clinical trials. 
 
 
4. 4. Activation of mTOR in a subgroup of ovarian carcinomas: correlation with 
p-eIF-4E and prognosis 
Noske A, Lindenberg JL, Darb-Esfahani S, Weichert W, Buckendahl AC, Röske A, 
Sehouli J, Dietel M, Denkert C. Oncol Rep 2008; 20:1409-17 
 
Since the PI3K/AKT pathway plays an important role in ovarian cancer progression, 
we consecutively analyzed downstream molecules like mTOR, 4E-BP1, and eIF4E. 
The mTOR pathway is involved in cell growth and protein translation. In the last few 
years, it has been shown that mTOR is an attractive target in anticancer therapy. As 
a basis for clinical trials, it is necessary to identify patients who might have a benefit 
of this therapy and to determine the status of these molecular targets in tumor 
tissues. We found an expression of p-mTOR in 47%, p-4E-BP1 in 30.5%, and p-eIF-
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4E in 55.7% of the primary ovarian carcinomas. Expression of p-mTOR was 
significantly associated with p-eIF-4E expression, and serous histological subtype.  
For p-4E-BP1, a significant relation to poorly differentiated (high-grade) carcinomas 
and higher mitotic rate was observed. In univariate Kaplan-Meier analysis, increased 
expression of p-mTOR and p-eIF-4E was related to better overall survival for patients 
with invasive cancer. In multivariate analysis, only postoperative residual tumor had 
significant independent prognostic information. We further connected the in vivo data 
with cell culture studies and found a different protein expression pattern of p-AKT, p-
mTOR, and p-4E-BP1 between ten ovarian cancer cell lines using western blot. We 
treated cancer cells with the mTOR inhibitor Rapamycin using different incubation 
times and concentrations. We found an inhibition of cell proliferation after Rapamycin 
incubation but we did not observe any effects on cell cycle and apoptosis in this cell 
type. Finally, we analyzed the protein expression of mTOR signalling components 
after Rapamycin treatment in three cancer cell lines. We observed a suppression of 
p-mTOR and p-4E-BP1 as well as an up-regulation of p-AKT. These data support the 
importance of this signalling pathway in ovarian carcinomas and suggest that mTOR 
inhibition may be effective in a subset of tumors. The design of future clinical trials 
should incorporate biomarker testing to determine predictive markers for response to 
mTOR inhibitors. 
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Figure 3 Immunohistochemical expression of p-mTOR in a high-grade serous 
ovarian carcinoma (A). Kaplan-Meier analysis displays a significant better overall 
survival in patients with ovarian carcinomas (B). Western blot analysis demonstrates 
a different expression pattern of molecules of the p-mTOR pathway (C). Rapamycin 
treated ovarian cancer cells show a reduced cell proliferation using an XTT assay 
(*p<0.05, two-sided t-test) (D). Rapamycin treatment reveals a over-expression of p-
AKT and reduced p-mTOR and p-4E-BP1 expression (E). 
 
 
4. 5. HMGA2 gene is a promising target for ovarian cancer silencing therapy 
Malek A, Bakhidze E, Noske A, Sers C, Aigner A, Schäfer R, Tschernitsa O. Int. J. 
Cancer 2008; 123: 348-356 
 
The goal of this study was to evaluate whether the HMGA2 gene can serve as a 
target for effective and safe silencing therapy of serous ovarian cancer.  The HMGA2 
protein belongs to the high mobility group family of nuclear nonhistone 
phosphoproteins. As one of the major nonhistone chromosomal proteins, HMGA  
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proteins are multifunctional and are involved in many cellular processes like 
chromatin organisation, cell-cycle control, differentiation, and cellular senescence. 
We investigated HMGA2 expression in 48 samples of serous ovarian carcinomas as 
well as five ovarian cancer cell lines. We observed an expression in 65% of the 
ovarian carcinomas but not in normal ovarian epithelium by using in situ RNA 
hybridization. Expression of HMGA2 at mRNA and protein levels was found in four 
cancer cell lines (OVCAR-3, SKOV-3, A27/80, OAW42) but not in CAOV-3 cells and 
immortalized human ovarian surface epithelial (HOSE) cells using RT-PCR and 
western blot. Transient silencing of HMGA2 gene by means of siRNA inhibited 
proliferation of those cancer cells which over-express this gene initially. Stable 
silencing of highly expressed HMGA2 gene by shRNAi in cancer cell lines resulted in 
growth inhibition because of G1 arrest and increase of apoptosis. Finally, we 
confirmed the antitumoral effect of HMGA2 knockdown in vivo. Systemic 
administration of a HMGA2-targeting construct resulted in suppression of 
subcutaneous tumor xenografts in athymic nude mice. These findings suggest that 
the HMGA2 gene represents a promising target for gene silencing therapy in ovarian 
cancer. 
 
 
4. 6. A prognostic gene expression index in ovarian cancer – validation across 
different independent data sets 
Denkert C, Budczies J, Darb-Esfahani S, Györffy B, Sehouli J, Könsgen D, Zeillinger 
R, Weichert W, Noske A, Buckendahl AC, Müller BM, Dietel M, Lage H. J Pathol 
2009; 218: 273-280 
 
In this study, we investigated the hypothesis that gene expression analysis of ovarian 
carcinomas may be used to identify patients with different outcomes independently of 
classical clinical predictors. We further aimed to validate these molecular markers 
using an independent data set. The development of such molecular markers will 
potentially allow the selection of those patients who will have benefit of standard 
therapeutic approaches or will have more profit of novel treatment strategies. We 
used a semi-supervised method for prediction of overall survival. At first Affymetrix 
gene expression analysis was performed from 80 ovarian carcinomas (TOC cohort) 
and used for the development of a predictive model. A 300-gene ovarian prognostic  
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index was generated and validated in a leave-one-out approach (Kaplan-Meier-
analysis, p=0.0087). In a second validation step, the prognostic power of this index 
was confirmed in an independent data set of 118 ovarian carcinomas (Dukes cohort, 
p=0.0063). In multivariate analysis, the ovarian prognostic index was independent of 
the post-operative residual tumor, the main prognostic factor in this disease. We then 
constructed a combined score of the molecular data and residual tumor status, which 
was able to define patient groups with highly significant differences in survival. Our 
findings suggest that gene expression analysis can be used to generate prognostic 
signatures in ovarian cancer that can be validated in independent data sets. The 
integrated analysis of gene expression data and residual tumor can be used for 
assessment of the prognosis of platinum-taxol-treated ovarian cancer. 
 
 
4. 7. IMP3 Expression in Human Ovarian Cancer is associated with improved 
survival  
Noske A*, Faggad A*, Wirtz R, Darb-Esfahani S, Sehouli J, Sinn B, Nielsen FC, 
Weichert W, Buckendahl AC, Röske A, Müller B, Dietel M, Denkert C. Int J Gyn 
Pathol 2009; 28:203-10 (*both authors contributed equally) 
 
In this study, we investigated the expression of IMP3 in a cohort of primary ovarian 
carcinomas as well as in ovarian cancer cell lines. The IGF-II mRNA-binding protein 
IMP3 plays an important role in embryogenesis and recent reports suggest an 
involvement in tumorigenesis. We observed an increased IMP3 protein expression in 
a subset of ovarian carcinomas that was significantly associated with better overall 
survival in a univariate Kaplan-Meier analysis. We confirmed these findings by a 
complementary method and investigated IMP3 mRNA expression in FFPE ovarian 
cancer specimens by real time quantitative RT-PCR. We found a highly significant 
correlation between protein and mRNA levels as well as a correlation of IMP3 mRNA 
expression with patient overall survival. We further found a protein expression in 
various ovarian cancer cell lines. Our results show an expression of IMP3 at protein 
and mRNA level in a subpopulation of ovarian cancer. These data suggest that IMP3 
might be involved in progression of ovarian cancer.  
 
 
 19
5. Conclusions 
 
In this thesis, we investigated the expression of Gelsolin, CRM1, AKT, p-mTOR, p-
4E-BP1, eIF-4e, HMGA2, and IMP3 in primary epithelial ovarian carcinomas as well 
as in ovarian cancer cells. We observed an expression of all molecules in a subset of 
ovarian carcinomas. Most of them were associated with certain clinical and 
pathological characteristics as well as with patient survival. In functional studies, 
these molecules were involved in cell proliferation and showed tumor growth 
suppressive activity which might be interesting for anticancer treatment strategies. 
 
In this regard, our findings confirm that the AKT/mTOR signalling pathway is 
hyperactivated in ovarian cancer. This pathway is frequently deregulated in ovarian 
cancer and plays an important role in tumor progression. Therefore, mTOR inhibition 
is an attractive target for antitumoral therapeutic approaches. Phase I-II trials are now 
ongoing with mTOR inhibitors in ovarian cancer patients [28]. Since mTOR inhibition 
may result in hyperactivation of AKT, combination therapies with PI3K/AKT and 
MAPK-inhibitors might be necessary to overcome such feedback mechanisms.  
A crucial challenge for future studies will be to identify predictive biomarkers which 
will indicate the benefit from mTOR inhibition or other specific therapies.  
 
To our knowledge, we investigated for the first time the expression of the export 
protein CRM1 in ovarian cancer specimens. It is important for transport of tumor 
relevant molecules like p53, COX-2 and EGFR. Therefore it is an interesting novel 
target for anticancer treatment. New nuclear export inhibitors (NEI) have recently 
shown potent antitumor effects in mouse models [29]. 
 
Taken together, the investigated molecules play a role in different cellular processes 
such as cell migration, cell growth and survival and alterations may contribute to the 
genesis and progression of ovarian carcinomas. In view of the heterogeneous 
biology, there is no predominant pathway that is deregulated in this tumor type. All of 
these defects observed within this tumor are most likely passengers and only a 
fraction belongs to specific operators (“drivers”). Thus, the main challenge for the 
future will be the identification of the “drivers” in epithelial ovarian cancer which will 
enable to design more effective markers and drugs for the patients [30]. 
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Finally, more evidence became available that histological subtypes of ovarian cancer 
show different molecular alterations and biological behaviour. Therefore, subgroup 
analysis within histological subtypes should be implemented in future clinical trials.  
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10. Abbreviations 
 
AKT  protein kinase B (PKB/AKT) 
BRCA  Breast cancer gene 1 and 2 
CRM1  chromosomal region maintenance/ exportin 1 
COX-2  cyclooxygenase 2 
4E-BP1 eukaryotic translation inhibition factor 4E binding protein 
EGFR  epidermal growth factor receptor 
eIF-4E eukaryotic initiation factor 4E 
ErbB2  human epidermal growth factor receptor 2 
FACS  fluorescence activated cell sorting 
FIGO  Fédération Internationale de Gynécologie et d’Obstétrique 
HMGA2 high mobility group A2 gene 
IMP3  insulin-like growth factor-II (IGF-II) mRNA binding protein  
KRAS  kirsten rat sarcoma 
mTOR  mammalian target of Rapamycin 
LMB   Leptomycin 1  
PI3K   phosphatidylinositol-3-kinase 
TOC  Tumor bank ovarian cancer network 
XTT   colorimetric assay based on sodium 3´-[1-(phenylaminocarbonyl)- 3,4-
tetrazolium]-bis (4-methoxy-6-nitro) benzene sulfonic acid hydrate  
 
